ArticleCureus2026
Renal Amyloidosis: An Approach to Uniform Biopsy Reporting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal amyloidosis results in progressive renal failure, and consistent biopsy reporting improves prognostic accuracy and permits interinstitutional comparisons.
objectivesThis study aims to apply the histopathologic classification of Sen and Sarsik, calculate the Renal Amyloid Prognostic Score (RAPS), and correlate histological grade with clinical severity.
methodsWe retrospectively analyzed 18 biopsy-proven cases of renal amyloidosis out of 1,008 native renal biopsies performed at IMS & SUM Hospital, Siksha 'O' Anusandhan (Deemed University), Bhubaneswar, Odisha, India, between January 2021 and January 2026. Glomerular amyloid pattern (GAP) classes I-VI, RAPS, and final histologic grade (0-3) were assigned. Clinical data included age, sex, 24-hour protein, urea, creatinine, and underlying diagnosis. Statistical analyses used independent t tests, Fisher's exact test, and Spearman correlation.
resultsThe prevalence was 1.78%. The majority were primary amyloid light chain (AL) (12/18). Glomerular deposition was universal, with GAP class IV (15/18) predominating, associated with Grade 3. Grade 3 had significantly higher 24-hour proteinuria and serum creatinine than Grade 2 (P = 0.006 and P = 0.042). RAPS correlated positively with proteinuria (r = 0.68, P < 0.01) and creatinine (r = 0.59, P < 0.05). Conclusions: RAPS and histologic grading provide a consistent evaluation of renal amyloid burden, correlating with clinical severity. Prompt biopsies and standardized reporting can inform prognosis and guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.